Apa-RP Study: ADT + Apalutamide (Erleada)

We all spend considerable time and effort looking at pCA information. One of the studies that keeps rising to the surface, for me, is this one:
https://www.targetedonc.com/view/apalutamide-adt-delivers-100-rfs-at-2-years-in-high-risk-prostate-cancer
Specifically, wow, what a response - 100% without BCR! That is remarkable. I feel like this will be a standard of care, but we are not there yet. Just wondering what others think or have experienced. Thanks.

Steve

"Treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT) led to a biochemical recurrence (BCR)-free survival rate of 100% (90% CI, 93.0-100.0) at 24 months among patients with high-risk localized prostate cancer who have undergone radical prostatectomy (RP)."